They found the differences in the gene for a molecule called the dopamine D2 receptor (DRD2), a protein present on brain cells that are sensitive to the neurotransmitter dopamine.
The receptor is known to play a key role in memory and in a variety of mental illnesses. Most antipsychotic drugs work at least in part by blocking this protein, but scientists don’t yet understand how this helps patients. Nor can they explain why some people respond well to certain antipsychotic drugs and others respond poorly.
“Our study shows that these differences affect normal brain activity and memory processing, and therefore may also be important in mental illness,” says principal investigator Wolfgang Sadee, program director in pharmacogenomics at the Ohio State University Medical Center.
The findings could lead to tests that will enable doctors to match patients with certain mental illnesses to the most effective therapy, something they cannot do now.
The study was done in collaboration with Professor Alessandro Bertolino, University of Bari, Italy, who performed the clinical research. It is published online in the Proceedings of the National Academy of Sciences.
“Identifying these predictive markers is important because antipsychotic drugs are effective in only a portion of patients upon first treatment, and it takes a month or more to establish their efficacy,” says Sadee, who is also a professor of psychiatry and chair of the department of pharmacology.
“During this time, irreparable damage can result if the wrong antipsychotic is given to a patient.”
Sadee notes that the D2 receptor gene has been implicated in mental illness for some time, but that a variety of clinical studies have failed to consistently link variations in the gene to disease.
These findings may change that.
For this study, Sadee and his colleagues analyzed 68 autopsy samples of normal human brain tissue. For each case, the researchers measured and compared the amount of messenger RNA made by each of the two copies of the DRD2 gene. Messenger RNA is a molecule made when a gene is involved in making its protein.
In 15 of the 68 cases, the relative amounts of messenger RNA made by one gene in the pair was strikingly different from the amount made by the other. The disparity was a clue that something was different between the genes.
Comparisons of these DRD2 genes to the rest revealed three small differences in the DNA called single-nucleotide polymorphisms, or SNPs (pronounced ‘snips’).
SNPs are tiny natural variations between individuals that occur at certain positions in genes, providing landmarks in the genome.
SNPs often have no effect on the function of the gene or its protein, but, in this case, laboratory experiments showed that particular changes in two of the SNPs alters how the messenger RNA for DRD2 is processed.
That, in turn, changed the relative amounts of two variants of the protein that are made by the gene.
“The two variants of DRD2 have distinct functions, facilitating or inhibiting dopaminergic transmission, so that a change in their ratios is potentially critical,” Sadee says. “We believed that this change would enhance dopamine activity in the brain.”
The researchers then tested this hypothesis in normal human volunteers who took simple memory performance tests. The participants’ brain activity was monitored during the testing by functional magnetic resonance imaging (fMRI).
The results showed that volunteers with the two variant SNPs had significantly more brain activity than the usual SNPs for the same memory task.
“Their brain needed to ‘work’ more to get the same result,” Sadee says. The two SNPs were also associated with reduced memory performance and attentional control.
Sadee and his colleagues are now testing the relevance of the SNP markers in patients with schizophrenia and in patients with cocaine addiction.
Darrell E. Ward | EurekAlert!
Colorectal cancer: Increased life expectancy thanks to individualised therapies
20.02.2020 | Christian-Albrechts-Universität zu Kiel
Sweet beaks: What Galapagos finches and marine bacteria have in common
20.02.2020 | Max-Planck-Institut für Marine Mikrobiologie
The operational speed of semiconductors in various electronic and optoelectronic devices is limited to several gigahertz (a billion oscillations per second). This constrains the upper limit of the operational speed of computing. Now researchers from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg, Germany, and the Indian Institute of Technology in Bombay have explained how these processes can be sped up through the use of light waves and defected solid materials.
Light waves perform several hundred trillion oscillations per second. Hence, it is natural to envision employing light oscillations to drive the electronic...
Most natural and artificial surfaces are rough: metals and even glasses that appear smooth to the naked eye can look like jagged mountain ranges under the microscope. There is currently no uniform theory about the origin of this roughness despite it being observed on all scales, from the atomic to the tectonic. Scientists suspect that the rough surface is formed by irreversible plastic deformation that occurs in many processes of mechanical machining of components such as milling.
Prof. Dr. Lars Pastewka from the Simulation group at the Department of Microsystems Engineering at the University of Freiburg and his team have simulated such...
Investigation of the temperature dependence of the skyrmion Hall effect reveals further insights into possible new data storage devices
The joint research project of Johannes Gutenberg University Mainz (JGU) and the Massachusetts Institute of Technology (MIT) that had previously demonstrated...
Researchers at Chalmers University of Technology, Sweden, recently completed a 5-year research project looking at how to make fibre optic communications systems more energy efficient. Among their proposals are smart, error-correcting data chip circuits, which they refined to be 10 times less energy consumptive. The project has yielded several scientific articles, in publications including Nature Communications.
Streaming films and music, scrolling through social media, and using cloud-based storage services are everyday activities now.
After helping develop a new approach for organic synthesis -- carbon-hydrogen functionalization -- scientists at Emory University are now showing how this approach may apply to drug discovery. Nature Catalysis published their most recent work -- a streamlined process for making a three-dimensional scaffold of keen interest to the pharmaceutical industry.
"Our tools open up whole new chemical space for potential drug targets," says Huw Davies, Emory professor of organic chemistry and senior author of the paper.
12.02.2020 | Event News
16.01.2020 | Event News
15.01.2020 | Event News
21.02.2020 | Medical Engineering
21.02.2020 | Health and Medicine
21.02.2020 | Physics and Astronomy